Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | President and COO | October 09, 2026 | October 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 377,802 |
Ending reported balance
After 2026-10-13 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-10-09 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 2 · 2026-10-09 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-10-12 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 4 · 2026-10-12 · Sale · Disposed 9,181 · Balance 380,502 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 5 · 2026-10-12 · Sale · Disposed 2,700 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 6 · 2026-10-13 · Exercise / conversion · Acquired 11,881 · Balance 389,683 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Row 7 · 2026-10-13 · Sale · Disposed 11,881 · Balance 377,802 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 296,610 |
Reported balance
After 2026-10-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-09 · Exercise / conversion · Disposed 11,881 · Balance 296,610 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 284,729 |
Reported balance
After 2026-10-12 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-10-12 · Exercise / conversion · Disposed 11,881 · Balance 284,729 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.14 · Expires 2032-03-04 | Direct | 272,848 |
Reported balance
After 2026-10-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-10-13 · Exercise / conversion · Disposed 11,881 · Balance 272,848 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
F2: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.99 to $26.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.82 to $25.81, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.83 to $26.31, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F5: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.10 to $25.80, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F6: The option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 400 | $12.14 | $4,856.00 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 662,931 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 10, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 662,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · derivative · entry 13 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 403,939 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · derivative · entry 12 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,715 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 30,941 | $14.79 | $457,617.39 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 647,809 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.24 to $15.15, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 678,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 666,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 415,820 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · derivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,437 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 30,941 | $15.14 | $468,446.74 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 652,147 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.83 to $15.65, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 683,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 00:04 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000006 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 671,207 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 16 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,701 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 15 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,159 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 30,941 | $16.00 | $495,056.00 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 10 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 575,235 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F5 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.74 to $16.30, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 9 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 606,176 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 8 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 594,295 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 14 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 439,582 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 13 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 165,881 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 30,941 | $16.60 | $513,620.60 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 7 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 579,573 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F4 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 to $16.94, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 6 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 610,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 598,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 04, 2026 Filed Mar 7, 2026 00:25 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 81,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001780664-26-000004 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,485 Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 11,881 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 12 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 451,463 Underlying: Common Stock · 11,881 shares Expires 2032-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F7 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (right to buy) · Derivative | 14,722 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · derivative · entry 11 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,603 Underlying: Common Stock · 14,722 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 6,518 | $16.33 | $106,438.94 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 583,911 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F3 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.11 to $16.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 24,423 | $15.49 | $378,312.27 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 590,429 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. F2 · price: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $16.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 11,881 | $12.14 | $144,235.34 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 614,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 03, 2026 Filed Mar 6, 2026 00:42 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 14,722 | $6.55 | $96,429.10 |
DisclosureSEC source: 0001780664-26-000002 · primary_doc.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 602,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 19,461 | $6.99 | $136,032.39 |
DisclosureSEC source: 0001062993-25-004811 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 588,249 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2025 Filed Mar 7, 2025 00:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 40,044 | $6.98 | $279,507.12 |
DisclosureSEC source: 0001062993-25-004811 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 607,710 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 00:19 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-004811 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 647,754 Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 13,490 | $3.56 | $48,024.40 |
DisclosureSEC source: 0001062993-24-005761 · form4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,754 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 25,580 | $3.43 | $87,739.40 |
DisclosureSEC source: 0001062993-24-005761 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 486,244 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:41 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-005761 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 511,824 Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (right to buy) · Derivative | 199,549 | $0.00 Strike: $8.46 | $0.00 |
DisclosureSEC source: 0001062993-23-006323 · form4.xml · derivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,549 Underlying: Common Stock · 199,549 shares Expires 2033-03-06 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereunder at the end of each full month of continuous service until fully vested. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 22,668 | $8.57 | $194,264.76 |
DisclosureSEC source: 0001062993-23-006323 · form4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,824 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by Issuer's election under the equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 132,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-006323 · form4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,492 Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 02:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,613 | $12.01 | $55,402.13 |
DisclosureSEC source: 0001209191-22-017399 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,513 F1 · kind: This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 463,344 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-017399 · doc4.xml · derivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,344 Underlying: Common Stock · 463,344 shares Expires 2032-03-04 F2 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 02:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 185,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017399 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,126 Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 114,469 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-21-018744 · doc4.xml · derivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,469 Underlying: Common Stock · 114,469 shares Expires 2021-03-04 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 45,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018744 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,788 Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-017307 · doc4.xml · derivative · entry 5 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,325 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 845 | $58.99 | $49,846.55 |
DisclosureSEC source: 0001209191-21-017307 · doc4.xml · nonDerivative · entry 4 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.96 to 59.02, inclusive. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,471 | $58.64 | $555,379.44 |
DisclosureSEC source: 0001209191-21-017307 · doc4.xml · nonDerivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.955 to 58.95, inclusive. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 4,684 | $57.54 | $269,517.36 |
DisclosureSEC source: 0001209191-21-017307 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,316 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.95 to 57.93, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 15,000 | $6.55 | $98,250.00 |
DisclosureSEC source: 0001209191-21-017307 · doc4.xml · nonDerivative · entry 1 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-015501 · doc4.xml · derivative · entry 3 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,325 Underlying: Common Stock · 15,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| February 26, 2021 Filed Mar 2, 2021 02:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 15,000 | $56.23 | $843,450.00 |
DisclosureSEC source: 0001209191-21-015501 · doc4.xml · nonDerivative · entry 2 RUBINSTEIN JULIE · CIK 0001780664 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.01 to 56.66, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.